[Xingqi Eye Medicine: SQ-25012 injection received clinical trial approval notice] On September 15th, Xingqi Eye Medicine (300573.SZ) announced that the company received the "Drug Clinical Trial Approval Notice" for SQ-25012 injection issued by the State Food and Drug Administration and agreed to conduct clinical trials for the treatment of thyroid eye disease. This drug is a recombinant humanized IgG1 type trispecific antibody and is a Category 1 innovative drug for therapeutic biological products. The company has completed pharmaceutical and non-clinical pharmacology and toxicology studies, and the results show that it has good safety and clinical development value. As of the date of the announcement, no drugs of the same type have been approved for marketing.